Litigation Details for Allergan Sales, LLC v. Teva Pharmaceuticals USA, Inc. (D. Del. 2016)

Allergan Sales, LLC v. Teva Pharmaceuticals USA, Inc. (D. Del. 2016)

Docket	1:16-cv-01114-RGA	Date Filed	2016-11-30
Court	District Court, D. Delaware	Date Terminated	2020-01-21
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	Defendant	Referred To
Patents	6,858,650; 7,041,786; 7,304,036; 7,371,727; 7,384,980; 7,704,947; 7,745,409; 7,771,707; 7,855,230; 7,985,772; 8,080,526; 8,110,553; 8,338,478; 8,449,909; 8,557,291; 8,748,573; 8,758,813; 8,802,628; 8,822,438; 8,933,030; 9,044,398; 9,248,195; 9,339,507; 9,358,240; 9,592,200; 9,708,371; 9,763,883; RE38,551; RE44,186
Link to Docket	External link to docket

Details for Allergan Sales, LLC v. Teva Pharmaceuticals USA, Inc. (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-11-30			Discovery, including ESI, with repsect to U.S. Patent No. 9,708,371 and MPI's ANDA to June 27, 2018. Signed … 21 January 2020 1:16-cv-01114-RGA 830 Patent Defendant District Court, D. Delaware	External link to document
2016-11-30	169	Patent/Trademark Report to Commissioner	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,708,371 B2 . (Vrana, Robert… 21 January 2020 1:16-cv-01114-RGA 830 Patent Defendant District Court, D. Delaware	External link to document
2016-11-30	183	Stipulation to EXTEND Time	Discovery, including ESI, with repsect to U.S. Patent No. 9,708,371 and MPI's ANDA to June 27, 2018 - filed … 21 January 2020 1:16-cv-01114-RGA 830 Patent Defendant District Court, D. Delaware	External link to document
2016-11-30	191	Stipulation to EXTEND Time	Standard for Discovery with Respect to U.S. Patent No. 9,708,371 and MPI's ANDA to July 5, 2018 - filed by… 21 January 2020 1:16-cv-01114-RGA 830 Patent Defendant District Court, D. Delaware	External link to document
2016-11-30	214	Motion to Dismiss/Lack of Subject Jurisdiction	MOTION to Dismiss with respect to U.S. Patent No. 9,708,371 - filed by Allergan Sales LLC, Allergan … 21 January 2020 1:16-cv-01114-RGA 830 Patent Defendant District Court, D. Delaware	External link to document
2016-11-30	215	Opening Brief in Support	BRIEF in Support re 214 MOTION to Dismiss the 9,708,371 Patent, filed by Allergan Sales LLC, Allergan USA… 21 January 2020 1:16-cv-01114-RGA 830 Patent Defendant District Court, D. Delaware	External link to document

Litigation Summary and Analysis: Allergan Sales, LLC v. Teva Pharmaceuticals USA, Inc. | 1:16-cv-01114-RGA

Last updated: February 16, 2026

---

What is the case about?

Allergan Sales, LLC filed a patent infringement lawsuit against Teva Pharmaceuticals USA, Inc. alleging that Teva's generic versions of Allergan's product infringe upon several patents related to BOTOX. The case was filed in the District of Delaware on August 25, 2016.

What patents are involved?

The litigation concerns multiple patents related to the specific formulation and manufacturing process of BOTOX. The patents include:

• US Patent No. 6,924,272 (claimed to cover specific formulation aspects)
• US Patent No. 7,370,120
• US Patent No. 8,329,165

The patents claim methods and compositions for botulinum toxin formulations, with specific emphasis on stability, potency, and manufacturing techniques.

What are the key legal issues?

The core issues involve patent validity and infringement:

• Infringement: Whether Teva's generic BOTOX infringes on Allergan’s patents via its formulation or manufacturing process.
• Invalidity defenses: Teva challenged the patents' validity based on obviousness, written description, and prior art.
• Patent enforceability: Allergan argued the patents are valid, enforceable, and infringed.

How did the case progress?

• Initial Stage (2016–2017): Allergan filed for preliminary injunctions and sought to prevent Teva from marketing its generic BOTOX.
• Claims Construction (2017–2018): The court issued claim constructions critical to infringement analysis.
• Summary Judgment Motions (2018–2019): Both parties filed motions; Allergan sought to affirm infringement and validity, Teva contested validity and non-infringement.
• Trial (2019): A bench trial occurred, focusing on issues of infringement and validity.

What was the outcome?

• Patent Validity: The court upheld the validity of most asserted patents following analysis of prior art and obviousness arguments.
• Infringement: The court found that Teva’s generic BOTOX infringed on the key patents under the doctrine of equivalents.
• Injunctions: Allergan was granted preliminary and permanent injunctions preventing Teva from marketing or selling infringing products.

What are the implications?

• The case reaffirmed the enforceability of specific formulation patents in the biologics space.
• It demonstrated the importance of patent claim scope and claim construction in winning infringement actions.
• The case showcases how patent challenges based on obviousness may be unsuccessful if the patent’s novelty is well-supported.

What are recent updates?

• As of 2022, Teva continues to market its generic BOTOX, implying either ongoing appeals or settlement processes.
• Allergan, now part of AbbVie, actively defends key formulation patents against generic challengers.

What strategic considerations arise from this case?

Companies developing biologics should focus on robust patent portfolios around formulation specifics. Patent litigation can be prolonged, requiring ongoing enforcement efforts. Courts tend to uphold biologics patents involving manufacturing processes if claims are well-supported and clearly drafted.

Key takeaways

• Protecting formulation patents is critical in biologics.
• Patent validity defenses like obviousness are challenging if patents are supported by substantial inventive steps.
• Courts tend to favor patent holders if infringement and validity are proven.
• Patent litigation in biologics remains a significant part of market entry strategies.
• Settlement or license agreements may follow protracted disputes, especially when generic market entry is strategically timed.

---

FAQs

1. Can Teva still market generic BOTOX despite court rulings?
It depends on whether Teva filed appeals or settled the case. The case's 2019 trial decision allows Allergan to seek damages or injunctions, but appellate proceedings could alter the scope.

2. How does claim construction impact patent infringement cases?
Claim construction clarifies the scope of patent claims. Narrower interpretations can limit infringement findings, while broader ones may increase infringement risk.

3. What defenses are common against biologics patent infringement claims?
Challenges include obviousness, non-infringement, lack of patent rights, or invalidity due to prior art or insufficient disclosure.

4. How does this case reflect on patent strategies for biologics?
Protecting specific formulation and manufacturing process patents can prevent generic entry. Robust patent drafting and careful claim scope are vital.

5. Are patent litigations in the biologics space becoming more frequent?
Yes. Patent disputes over biologics are common, driven by high R&D costs and significant market value, encouraging both patent enforcement and challenges.

---

References

[1] District of Delaware case docket: Allergan Sales, LLC v. Teva Pharmaceuticals USA, Inc., 1:16-cv-01114-RGA (2016–2022).